Recommended dose and dose modifications1
Interrupt, reduce, and/or discontinue LENVIMA based on type and/or severity (grade) of AR
Capsules pictured are not actual size.
- In SELECT, ARs led to dose reductions in 68% of patients receiving LENVIMA1
- Treatment discontinuation due to ARs occurred in 18% of patients receiving LENVIMA1
- aReduce dose in succession based on the previous dose level (20 mg, 14 mg, or 10 mg per day).
For the management of specific adverse reactions, please see the AR management section below.
AR management
Help manage ARs with PI-guided strategies
Click on the bar of each AR for Pl-guided strategies. For the complete list of ARs, see full Prescribing Information.
-
Decreased appetite
PI-guided strategies to help manage decreased appetite1
-
Decreased weight
PI-guided strategies to help manage decreased weight1
CTCAE v4.0 does not define grade 4 decreased weight. Permanently discontinue for grade 4 adverse reactions.
-
Diarrhea
PI-guided strategies to help manage diarrhea1
Promptly initiate management of diarrhea. Withhold and resume at a reduced dose upon recovery, or permanently discontinue LENVIMA based on severity.1
-
Hypertension
PI-guided strategies to help manage hypertension1
Control BP prior to initiating treatment with LENVIMA
-
Fatigue
PI-guided strategies to help manage fatigue1
CTCAE v4.0 does not define grade 4 fatigue. Permanently discontinue for grade 4 adverse reactions
-
Nausea
PI-guided strategies to help manage nausea1
CTCAE v4.0 does not define grade 4 nausea. Permanently discontinue for grade 4 adverse reactions.
-
Proteinuria
PI-guided strategies to help manage proteinuria1
AR=adverse reaction; SELECT=Study of (E7080) LEnvatinib in Differentiated Cancer of the Thyroid; PI=Prescribing Information; CTCAE=Common Terminology Criteria for Adverse Events; BP=blood pressure.
